Cytokinetics INC Form 4 insider transactions

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the exercise of stock options and subsequent sale of common stock on April 8, 2025.

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 2,886 shares of common stock at a price of $35.78 on April 7, 2025.

Director Robert Arthur Harrington sold 450 shares of Cytokinetics Inc. common stock at a price of $39.43 on April 3, 2025.

Cytokinetics CEO Robert Blum sold 15,000 shares of common stock at $40.75 on March 31, 2025, according to a Form 4 filing.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports a gift of 200 shares of common stock.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold a portion of the acquired shares on March 18, 2025.

Sung Lee, EVP and CFO of Cytokinetics, reports the acquisition of common stock and stock options, along with the disposal of common stock, as per a recent SEC Form 4 filing.

EVP, Chief Commercial Officer of Cytokinetics, Andrew Callos, reports acquisition and disposal of common stock and derivative securities.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports acquisition of restricted stock units and stock options, as well as disposal of common stock.

Robert Blum, President & CEO of Cytokinetics, reports acquisition of restricted stock units and stock options, along with disposition of common stock.

EVP and Chief Commercial Officer of Cytokinetics, Andrew Callos, sold 2,775 shares of common stock on March 17, 2025, to cover the vesting of restricted stock units.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc, sold 4,389 shares of common stock on March 17, 2025, to cover taxes associated with the vesting of restricted stock units.

Cytokinetics CEO Robert Blum sold shares of common stock on March 17, 2025, to cover taxes associated with the vesting of restricted stock units.

Cytokinetics' President and CEO, Robert I. Blum, sold 25,000 shares of common stock at a price of $44.65 on March 17, 2025.

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, exercised stock options and sold shares on March 17, 2025.

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, exercised stock options and sold a portion of the acquired shares on March 14, 2025.

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 26,771 shares of common stock on March 13, 2025, at a price of $43.62 per share.

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 3,341 shares of common stock on March 6, 2025, to cover a transaction related to the vesting of restricted stock units.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc, sold 8,228 shares of common stock on March 6, 2025, to cover a transaction related to the vesting of restricted stock units.

Cytokinetics CEO Robert Blum sold 16,970 shares of common stock on March 6, 2025, to cover taxes associated with the vesting of restricted stock units.

Cytokinetics' CEO, Robert Blum, sold 25,000 shares of common stock at a price of $43.23 on March 5, 2025.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc, sold 2,449 shares of common stock on March 3, 2025, to cover a transaction related to the vesting of restricted stock units.

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 1,114 shares of common stock on March 3, 2025, to cover a transaction related to the vesting of restricted stock units.

Cytokinetics' CEO, Robert Blum, sold 8,743 shares of common stock at $42.88 to cover a transaction related to the vesting of restricted stock units.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold a portion of the acquired shares on March 4, 2025.

Director Robert Harrington sold 900 shares of Cytokinetics Inc. (CYTK) at $42.5 per share on March 4, 2025.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the acquisition and disposal of common stock and derivative securities.

Robert E. Landry, a director of Cytokinetics Inc., was granted stock options to purchase 25,538 shares of common stock.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on February 4, 2025.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, exercised stock options and sold a portion of the acquired shares on January 21, 2025.